We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Brain Cytokine Inhibits Cancer Spread While Protecting Neurons

By LabMedica International staff writers
Posted on 17 Jan 2012
Cancers that have spread to the brain have decreased pigment epithelium–derived factor (PEDF) activity, which may be linked to the poor prognosis for patients in this condition.

Previous studies have found that the cytokine PEDF was downregulated in resected human brain metastases of breast cancer compared with primary breast tumors, suggesting that restoring its expression might limit metastatic spread. More...


PEDF is a member of the serpin family, although it does not display the serine protease-inhibitory activity shown by many of the other serpin family members. The protein is secreted and it strongly inhibits angiogenesis. In addition, this protein is a neurotrophic factor involved in neuronal differentiation in retinoblastoma cells.

Investigators at the [US] National Cancer Institute (Bethesda, MD, USA) performed in vitro analyses as well as direct intracranial implantation in a mouse model to study metastasis of breast cancer tumors into the brain.

They reported in the January 1, 2012, issue of the journal Cancer Research that outgrowth of large experimental brain metastases from human 231-BR or murine 4T1-BR breast cancer cells was suppressed by PEDF expression. The suppressive effects of PEDF were not only rapid but also independent of the effects of this factor on angiogenesis. Paralleling its cytotoxic effects on breast cancer cells, PEDF also exerted a prosurvival effect on neurons that shielded the brain from tumor-induced damage, as indicated by a relative 3.5-fold reduction in the number of dying neurons adjacent to tumors expressing PEDF.

PEDF is currently being studied as a therapy for macular degeneration because it has been shown to protect neurons in the retina. The potential value of PEDF in cancer therapy remains to be evaluated. “We are making progress from the neck down in cancer treatment, but brain metastases are increasing and are often a primary reason patients with breast cancer do not survive,” said senior author Dr. Patricia S. Steeg, head of the women's cancers section at the [US] National Cancer Institute.

Related Links:

National Cancer Institute



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.